Buprenorphine for Long-Term Chronic Pain Management: Still Looking for the Evidence

2020 ◽  
Vol 172 (4) ◽  
pp. 293
Author(s):  
Michael E. Schatman ◽  
Hannah Shapiro ◽  
David J. DiBenedetto
2020 ◽  
Vol 172 (4) ◽  
pp. 294
Author(s):  
Roger Chou ◽  
Jane Ballantyne ◽  
Anna Lembke

2017 ◽  
Vol 7 (6) ◽  
pp. 484-487
Author(s):  
Robin Moorman Li, PharmD ◽  
Rachel Hrabchak Franks, PharmD ◽  
Steven G. Dimmitt, DO ◽  
George R. Wilson, MD

Nonmalignant chronic pain management involves an ongoing process of complex evaluations including proper patient selection, proper prescribing, and careful monitoring. In the Pain Management Refill Clinic, patients are stabilized on an opioid regimen by either a pain specialist or a primary care physician (PCP). The PCP assumes long-term prescription of the regimen and proper follow-up. The inclusion of pharmacists in the management of patients suffering from chronic pain has allowed the physicians to improve opioid prescribing, documentation, and monitoring in accordance with chronic nonmalignant pain guidelines.


2017 ◽  
Vol 32 (5) ◽  
pp. 558-567 ◽  
Author(s):  
Brandi L. Bowers ◽  
Andrew J. Crannage

Nationally, the prescription of opioids for acute and chronic pain is increasing. As opioid use continues to expand and become of increased concern for health-care practitioners, so do the adverse effects and long-term management of those effects. Opioid-induced constipation (OIC) presents a unique challenge because tolerance does not develop to this particular adverse effect, making chronic pain management a delicate balance between relieving pain and preventing long-term adverse effects such as constipation and dependence. Several agents have been developed for the treatment of OIC in patients with chronic noncancer pain on the basis of short-term studies of 12 weeks or less. However, chronic pain management often extends beyond this 12-week boundary, resulting in health-care professionals questioning the safety and efficacy of continued treatment with OIC agents. This review evaluates available literature on long-term treatment of OIC in patients with chronic noncancer pain with lubiprostone, naloxegol, and methylnaltrexone as well as preliminary results of the recently completed naldemedine long-term trial, COMPOSE-3.


2017 ◽  
Vol 35 (1) ◽  
pp. 117-134 ◽  
Author(s):  
Ladan Eshkevari

According to National Institute of Health Pathways to Prevention Workshop (2014), chronic pain affects an estimated 100 million Americans, with approximately 25 million people experiencing moderate to severe chronic pain, which negatively impacts their ability to function leading to a diminished quality of life. Pain is the primary reason Americans are on disability, which adds to the economic and social burden of suffering for the nation. Chronic pain costs are estimated to be between $560 and $630 billion per year. An estimated 5 to 8 million Americans use opioids for long-term management of chronic pain, which can have deleterious effects on their lives including addiction. Recent evidence suggests that acupuncture, a treatment modality that has been used worldwide for over 2,000 years, may provide a useful pain management option for those who suffer from chronic pain. The investigation into its mechanism of action and efficacy remains elusive, but promising.


Sign in / Sign up

Export Citation Format

Share Document